<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-id journal-id-type="pmc-domain-id">16</journal-id><journal-id journal-id-type="pmc-domain">bmccanc</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12781513</article-id><article-id pub-id-type="pmcid-ver">PMC12781513.1</article-id><article-id pub-id-type="pmcaid">12781513</article-id><article-id pub-id-type="pmcaiid">12781513</article-id><article-id pub-id-type="pmid">41310581</article-id><article-id pub-id-type="doi">10.1186/s12885-025-15381-5</article-id><article-id pub-id-type="publisher-id">15381</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Therapy-induced remodeling of IgG and plasma N-glycans in breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Mari&#269;i&#263; Vrban</surname><given-names initials="M">Martina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Radovani Trbojevi&#263;</surname><given-names initials="B">Barbara</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Visentin</surname><given-names initials="D">David</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramljak</surname><given-names initials="K">Katarina</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kirac</surname><given-names initials="I">Iva</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ga&#263;e</surname><given-names initials="M">Mihaela</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Milas</surname><given-names initials="I">Ivan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lauc</surname><given-names initials="G">Gordan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Primorac</surname><given-names initials="D">Dragan</given-names></name><address><email>draganprimorac2@gmail.com</email></address><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Gudelj</surname><given-names initials="I">Ivan</given-names></name><address><email>ivan.gudelj@uniri.hr</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00r9vb833</institution-id><institution-id institution-id-type="GRID">grid.412688.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0397 9648</institution-id><institution>University Hospital for Tumors, Sestre Milosrdnice University Hospital Center, </institution></institution-wrap>Zagreb, Croatia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05sw4wc49</institution-id><institution-id institution-id-type="GRID">grid.412680.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 1015 399X</institution-id><institution>Faculty of Medicine, </institution><institution>Josip Juraj Strossmayer University of Osijek, </institution></institution-wrap>Osijek, Croatia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03av1g763</institution-id><institution-id institution-id-type="GRID">grid.424982.1</institution-id><institution>Genos Glycoscience Research Laboratory, </institution></institution-wrap>Zagreb, Croatia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05r8dqr10</institution-id><institution-id institution-id-type="GRID">grid.22939.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2236 1630</institution-id><institution>Faculty of Biotechnology and Drug Development, </institution><institution>University of Rijeka, </institution></institution-wrap>Rijeka, Croatia </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05r8dqr10</institution-id><institution-id institution-id-type="GRID">grid.22939.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2236 1630</institution-id><institution>Faculty of Medicine, </institution><institution>University of Rijeka, </institution></institution-wrap>Rijeka, Croatia </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/022991v89</institution-id><institution-id institution-id-type="GRID">grid.440823.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0546 7013</institution-id><institution>School of Medicine, </institution><institution>Catholic University of Croatia, </institution></institution-wrap>Zagreb, Croatia </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00mv6sv71</institution-id><institution-id institution-id-type="GRID">grid.4808.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0657 4636</institution-id><institution>Faculty of Pharmacy and Biochemistry, </institution><institution>University of Zagreb, </institution></institution-wrap>Zagreb, Croatia </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05sw4wc49</institution-id><institution-id institution-id-type="GRID">grid.412680.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 1015 399X</institution-id><institution>Faculty of Dental Medicine and Health, </institution><institution>Josip Juraj Strossmayer University of Osijek, </institution></institution-wrap>Osijek, Croatia </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.518242.8</institution-id><institution>St. Catherine Specialty Hospital, </institution></institution-wrap>Zagreb, Croatia </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04p491231</institution-id><institution-id institution-id-type="GRID">grid.29857.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 5907 5867</institution-id><institution>Pennsylvania State University, </institution></institution-wrap>University Park, PA USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00zm4rq24</institution-id><institution-id institution-id-type="GRID">grid.266831.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2168 8754</institution-id><institution>The Henry C. Lee College of Criminal Justice and Forensic Sciences, </institution><institution>University of New Haven, </institution></institution-wrap>West Haven, CT USA </aff><aff id="Aff12"><label>12</label>Sana Kliniken Oberfranken, Coburg, Germany </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00m31ft63</institution-id><institution-id institution-id-type="GRID">grid.38603.3e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0644 1675</institution-id><institution>Faculty of Medicine, </institution><institution>University of Split, </institution></institution-wrap>Split, Croatia </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03fbv3w59</institution-id><institution-id institution-id-type="GRID">grid.464573.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1781 318X</institution-id><institution>National Forensic Sciences University, </institution></institution-wrap>Gujarat, India </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>11</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2026</year></pub-date><volume>26</volume><issue-id pub-id-type="pmc-issue-id">503764</issue-id><elocation-id>32</elocation-id><history><date date-type="received"><day>3</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>11</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-09 10:25:13.567"><day>09</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12885_2025_Article_15381.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Protein N-glycosylation plays a key role in cancer biology and may offer insights into tumor behavior and treatment response. This study investigated changes in N-glycosylation of immunoglobulin G (IgG) and total plasma proteins in patients with breast cancer undergoing neoadjuvant chemotherapy.</p></sec><sec><title>Methods</title><p id="Par2">A prospective cohort of 34 women with early-stage or locally advanced breast cancer was recruited. Plasma samples were collected before and after neoadjuvant chemotherapy. IgG was isolated by immunoaffinity chromatography, and IgG and total plasma N-glycans were enzymatically released, fluorescently labeled, and analyzed using ultra-high performance liquid chromatography. Glycan traits were expressed as relative abundances and summarized into derived structural features. Longitudinal changes were assessed using linear mixed-effects models adjusted for age and body mass index.</p></sec><sec><title>Results</title><p id="Par3">Chemotherapy induced significant decrease in IgG core fucosylation. This effect varied by treatment: anthracycline-based regimen led to decreased core fucosylation and digalactosylation and increased monogalactosylation. The greatest reduction in core fucosylation was observed in patients treated with docetaxel and cyclophosphamide. HER2-targeted therapy was associated with decreased bisecting N-acetylglucosamine. Plasma glycosylation remained largely stable, though oligomannose glycans increased in patients following chemotherapy. Tumor size was significantly associated with several plasma glycan traits, particularly digalactosylation and oligomannosylation.</p></sec><sec><title>Conclusions</title><p id="Par4">IgG glycosylation patterns change in a treatment-specific manner during chemotherapy, potentially reflecting immune modulation. Plasma glycan traits are more stable but may reflect tumor burden. These results support the potential of glycan profiling as a biomarker for monitoring the impact of therapy and disease progression in breast cancer.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12885-025-15381-5.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Breast cancer</kwd><kwd>Neoadjuvant chemotherapy</kwd><kwd>Immunoglobulin G</kwd><kwd>N-glycosylation</kwd><kwd>Plasma proteins</kwd><kwd>Glycan biomarkers</kwd><kwd>Glycoprofiling</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100018693</institution-id><institution>HORIZON EUROPE Framework Programme</institution></institution-wrap></funding-source><award-id>101159018</award-id><principal-award-recipient><name name-style="western"><surname>Primorac</surname><given-names>Dragan</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2026</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par50">Breast cancer is the most commonly diagnosed malignancy and a leading cause of cancer-related mortality among women worldwide, with over two million new cases annually [<xref ref-type="bibr" rid="CR1">1</xref>]. The incidence is increasing, particularly in North America, Australasia, and Western and Northern Europe, which are driven by lifestyle factors and expanded screening programs [<xref ref-type="bibr" rid="CR2">2</xref>]. Despite improvements in early detection and survival rates, particularly in developed countries, clinical management remains limited by tumor heterogeneity and variable treatment responses [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par51">Histologically, breast cancer includes invasive carcinoma of no special type (NST), lobular, mucinous, and tubular subtypes, with NST being the most prevalent [<xref ref-type="bibr" rid="CR3">3</xref>]. Its pathogenesis involves a combination of genetic, hormonal, and lifestyle-related factors. While <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic> mutations are well characterized, they account for only approximately 6% of cases. Other susceptibility genes, such as <italic toggle="yes">TP53</italic>,<italic toggle="yes"> PALB2</italic>,<italic toggle="yes"> ATM</italic>,<italic toggle="yes"> CHEK2</italic>, and <italic toggle="yes">PTEN</italic>, contribute to risk to a lesser extent [<xref ref-type="bibr" rid="CR4">4</xref>]. Hormonal exposures, including menopausal hormone therapy, have also been implicated [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par52">Advances in personalized medicine have allowed treatment decisions to be tailored to tumor biology and individual risk. Immunohistochemistry for estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 enables molecular subtyping into luminal A, luminal B, HER2-positive, and triple-negative breast cancer (TNBC), each with distinct prognostic and therapeutic implications [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Multigene expression panels such as Oncotype DX and Mammaprint are now integral to adjuvant therapy decisions, as supported by large trials including MINDACT and TAILORx [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par53">While traditional serum biomarkers such as CA 15 &#8722; 3 and CEA are used in monitoring, they are insufficiently specific or sensitive for diagnosis or early relapse detection [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Diagnosis and response assessment still rely on imaging and tissue biopsy, both of which are invasive or limited in frequency [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Thus, there is a pressing need for novel, minimally invasive biomarkers capable of reflecting disease activity in real time.</p><p id="Par54">Glycosylation, a posttranslational modification involving the enzymatic addition of glycans to proteins or lipids, is increasingly recognized for its role in cancer biology [<xref ref-type="bibr" rid="CR14">14</xref>]. Altered glycosylation affects cell signaling, immune recognition, and metastatic potential. In breast cancer, shifts in glycan structures contribute to immune evasion, inflammation, and tumor progression [<xref ref-type="bibr" rid="CR15">15</xref>]. Significant differences in glycosyltransferase activity have been observed between tumor and normal tissues [<xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>], and glycosylated protein expression differs markedly between primary tumors and developed metastases [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par55">A large proportion of circulating and tissue proteins are glycosylated, making glycoproteins promising candidates for noninvasive biomarker development [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par56">Aberrant protein glycosylation, particularly altered N-glycan branching, fucosylation, and sialylation, is a characteristic of breast cancer progression, metastasis and therapy resistance [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Specific plasma N-glycan traits, such as hypersialylation, oligomannosylation, increased branching, antennary fucosylation with elevated sialyl Lewis x (sLe<sup>x</sup>) epitope correlate with tumor invasiveness, circulating tumor cell burden and metastatic capacity [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref>]. Increased tetra- and hexa-fucosylated haptoglobin glycoforms have also been detected in breast cancer serum, improving differentiation between benign and malignant lesions when combined with classical tumor markers [<xref ref-type="bibr" rid="CR24">24</xref>]. Immunoglobulin G (IgG), a major circulating glycoprotein, undergoes distinct Fc-glycosylation rearrangement during carcinogenesis and systemic inflammation [<xref ref-type="bibr" rid="CR25">25</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>]. Altered IgG Fc glycosylation influences antibody-dependent cellular cytotoxicity (ADCC) and inflammatory pathways by modulating Fc&#947; receptor binding [<xref ref-type="bibr" rid="CR28">28</xref>]. Both total serum and IgG N-glycan profiling have emerged as promising minimally invasive approaches for cancer biomarker discovery. Elevated levels of branched, core fucosylated, and sialylated total serum N-glycans, along with core fucosylated and agalactosylated IgG structures, enable discrimination of early-stage breast cancer from healthy controls [<xref ref-type="bibr" rid="CR26">26</xref>]. Dynamic glycosylation changes during chemotherapy and endocrine therapy reflect immune modulation and treatment response [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], while IgG N-glycans have shown predictive value for therapeutic outcomes in gastric cancer [<xref ref-type="bibr" rid="CR30">30</xref>] and chronic inflammatory diseases [<xref ref-type="bibr" rid="CR31">31</xref>]. Together, these findings indicate that total plasma N-glycosylation and IgG glycosylation sensitively reflect tumor&#8211;host interactions and immune modulation, offering substantial potential for early detection, molecular subtyping and therapy monitoring in breast cancer. Nevertheless, variability among studies reflects tumor heterogeneity and supports the need for further glycomic analyses for reliable biomarker validation [<xref ref-type="bibr" rid="CR17">17</xref>]. Building on existing evidence, this study investigates IgG and total plasma N-glycosylation patterns in breast cancer patients undergoing neoadjuvant chemotherapy. The analysis focuses on therapy-induced glycan changes and their associations with treatment regimens, clinical response, and tumor size.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study participants</title><p id="Par57">This prospective cohort study enrolled 37 women aged 31&#8211;80 years with histologically confirmed, early-stage or locally advanced, nonmetastatic invasive breast cancer. Patients were recruited between 2021 and 2023 at the University Hospital for Tumors, Sestre Milosrdnice Clinical Hospital Center in Zagreb, Croatia. All patients were candidates for neoadjuvant chemotherapy on the basis of institutional treatment guidelines.</p><p id="Par58">The inclusion criteria were female sex, age&#8201;&#8805;&#8201;18 years, newly diagnosed nonmetastatic invasive breast cancer, and eligibility for systemic neoadjuvant therapy.</p><p id="Par59">The exclusion criteria included a prior history of breast cancer, ductal carcinoma in situ (DCIS), metastatic disease, or the luminal A subtype.</p><p id="Par60">Tumor staging and diagnosis were based on comprehensive clinical and radiological assessments, including bilateral digital mammography, breast and axillary ultrasound, breast MRI, and ultrasound-guided core biopsy. Additional staging modalities (CT, PET/CT, or bone scan) were used as clinically indicated. In premenopausal patients, breast MRI was timed to the luteal phase of the menstrual cycle (days 5&#8211;15).</p><p id="Par61">Systemic therapy commenced within 2&#8211;4 weeks of diagnosis and staging, in accordance with current evidence-based guidelines and tailored to tumor subtype, nodal status, and patient factors. Patients received standard neoadjuvant chemotherapy regimens including anthracycline-, taxane-, and cyclophosphamide-based protocols, with HER2-positive cases additionally treated with trastuzumab and pertuzumab. Detailed descriptions of all treatment regimens, dosing schedules, and monitoring procedures are provided in the Supplementary Appendix 1.</p><p id="Par62">The response to therapy was monitored with ultrasound (after paclitaxel cycle 4) and MRI (after cycle 12), followed by surgery (either breast-conserving or mastectomy) with sentinel or axillary lymph node biopsy as appropriate. Tumors were staged according to the 8th edition of the AJCC/UICC TNM classification, including both tumor size (T1c&#8211;T4b) and nodal involvement (N0&#8211;N3c), and were grouped into stages IA to IIIC.</p><p id="Par63">EDTA plasma samples for N-glycan profiling were obtained before starting chemotherapy and immediately prior to surgery, about one month after treatment completion. Although 37 patients were initially enrolled, samples from three were unavailable at either the first or second time point (T1 or T2), resulting in 34 patients included in the final analysis. The interval between the end of chemotherapy and sample collection was consistent across all patients.</p><p id="Par64">Additional laboratory tests included complete blood count, clinical biochemistry, and measurement of tumor markers (CA 15&#8201;&#8722;&#8201;3, CEA). Clinical treatment data were recorded prospectively. All participants provided written informed consent, and the study was approved by the local ethics committee in accordance with the Declaration of Helsinki.</p></sec><sec id="Sec5"><title>Methods</title><sec id="Sec7"><title>Isolation of IgG from plasma</title><p id="Par65">IgG was isolated from human plasma via a high-throughput immunoaffinity protocol on 96-well protein G monolithic plates (BIA Separations, Slovenia), as previously described [<xref ref-type="bibr" rid="CR32">32</xref>]. The plasma samples were diluted 1:7 in phosphate-buffered saline (PBS; Merck, Germany) and applied to the plate. After washing, the IgG was eluted with 0.1 M formic acid (Merck) and immediately neutralized with 1 M ammonium bicarbonate (Acros Organics, USA).</p></sec><sec id="Sec8"><title>N-glycan release from IgG and total plasma proteins</title><p id="Par66">The isolated IgG was vacuum-dried and denatured with 1.33% sodium dodecyl sulfate (SDS; Invitrogen, USA) at 65&#160;&#176;C for 10&#160;min. Total plasma proteins were treated similarly with 2% SDS. Following denaturation, 4% (v/v) Igepal-CA630 (Sigma Aldrich, USA) was added, and the samples were shaken for 15&#160;min. For each sample, N-glycans were enzymatically released through incubation with 1.2 U PNGase F (Promega, USA) at 37&#160;&#176;C overnight.</p></sec><sec id="Sec10"><title>Fluorescent labeling and solid-phase extraction</title><p id="Par67">The released N-glycans were fluorescently labeled with 2-aminobenzamide (2-AB) in 30% acetic acid in DMSO, followed by a 2-hour incubation at 65&#160;&#176;C. Excess label and reagents were removed via solid-phase extraction (SPE) with AcroPrep Advance 0.2&#160;&#956;m wwPTFE plates (Pall). The purified glycans were eluted with ultrapure water and stored at &#8722;&#8201;20&#160;&#176;C.</p></sec><sec id="Sec12"><title>Hydrophilic interaction ultra-high performance liquid chromatography</title><p id="Par68">The labeled glycans were separated via an Acquity UPLC H-Class system (Waters, USA) equipped with a fluorescence detector (excitation: 250&#160;nm, emission: 428&#160;nm). Separations were performed on a Waters BEH glycan column using 100 mM ammonium formate (pH 4.4) as mobile phase A and acetonitrile as mobile phase B.</p><p id="Par69">For IgG glycans, a linear gradient of 75&#8211;62% acetonitrile was applied at 0.4 mL/min over 27&#160;min. For total plasma glycans, a gradient of 70&#8211;53% acetonitrile at 0.56 mL/min over 25&#160;min was used.</p><p id="Par70">Chromatograms were processed via Empower 2 software (Waters). Peaks were manually adjusted to ensure consistent integration. The IgG glycan profiles were divided into 24 peaks (IGP1&#8211;IGP24), and the plasma profiles were divided into 39 peaks (GP1&#8211;GP39). The abundance was calculated as the percentage of the total chromatogram area. Six derived traits were computed for IgG and 16 for plasma proteins, reflecting key glycosylation features such as galactosylation, sialylation, fucosylation, oligomannosylationand bisecting N-acetylglucosamine.</p></sec></sec><sec id="Sec14"><title>Statistical analysis</title><p id="Par71">The glycan peak areas were normalized via total area normalization and log-transformed via R software (version 4.4.1; R Foundation for Statistical Computing). The glycan peaks were then back-transformed to calculate the derived traits (Supplementary Table 1). To meet model assumptions of normality, all glycan traits were transformed using rank-based inverse normal (RANKL) transformation (mean &#8211; 0, SD &#8211; 1). Differences in glycan traits between timepoints (before and after treatment) were assessed via paired linear mixed-effects models, with time as a fixed effect and individual samples as random effects. Age and BMI were included as covariates. Pairwise contrasts were tested via the emmeans package [link:&#160;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.tandfonline.com/doi/abs/10.1080/00031305.1980.10483031">https://www.tandfonline.com/doi/abs/10.1080/00031305.1980.10483031</ext-link>], and P values were adjusted via Benjamini&#8211;Hochberg false discovery rate correction.</p><p id="Par72">To quantify the power of between-therapy differences in the subgroup analysis, we computed &#951;<sup>2</sup> from a one-way ANOVA (&#916;&#8201;~&#8201;Therapy), converted to Cohen&#8217;s f, and calculated power with pwr.anova.test using the harmonic mean of the unbalanced group sizes (ACdd 22, TC 3, TCbHP 9 &#8594; &#8462; = 6.12 per group; k&#8201;=&#8201;3; &#945;&#8201;=&#8201;0.05).</p></sec></sec><sec id="Sec16"><title>Results</title><p id="Par73">This study analyzed 34 paired samples from female patients with breast cancer (age range, 31&#8211;80 years) treated at the University Hospital for Tumors, Sestre Milosrdnice Clinical Hospital Center, Zagreb, Croatia, between 2021 and 2023. IgG and total plasma N-glycosylation were assessed before and after neoadjuvant chemotherapy via 24 directly measured and 6 derived IgG glycan traits and 39 directly measured and 16 derived plasma glycan traits (Supplementary Table 1, Supplementary Fig.&#160;1).</p><p id="Par74">Owing to structural similarities among glycans and the limited sample size, statistical analyses were performed on derived glycan traits, which reflect key glycosylation features such as galactosylation, sialylation, fucosylation, and bisecting GlcNAc. Traits were rank-transformed and analyzed via linear mixed-effects models adjusted for age and BMI, with patient ID as a random effect.</p><p id="Par75">Analysis of longitudinal changes in IgG glycosylation revealed that only core fucosylation (CF) significantly decreased following chemotherapy (adjusted <italic toggle="yes">P</italic>&#8201;=&#8201;0.0047), indicating a potential shift toward more immunostimulatory IgG profiles (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>, Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). No other IgG glycosylation features changed significantly over time. Similarly, stratification by treatment response revealed no significant differences between patients with partial (PR) or complete response (CR) (Supplementary Table 2).</p><p id="Par76">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Longitudinal changes in IgG glycan traits adjusted for age and BMI</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Glycan Trait (IgG)</th><th align="left" colspan="1" rowspan="1">Effect (RANK)</th><th align="left" colspan="1" rowspan="1">Standard Error</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>&#160;Value</th><th align="left" colspan="1" rowspan="1">Adjusted <italic toggle="yes">P</italic>&#160;Value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">B</td><td align="left" colspan="1" rowspan="1">&#8722;0.1688</td><td align="left" colspan="1" rowspan="1">0.1205</td><td align="left" colspan="1" rowspan="1">0.1697</td><td align="left" colspan="1" rowspan="1">0.5090</td></tr><tr><td align="left" colspan="1" rowspan="1">CF</td><td align="left" colspan="1" rowspan="1">&#8722;0.3422</td><td align="left" colspan="1" rowspan="1">0.0933</td><td align="left" colspan="1" rowspan="1">
<bold>0.0008</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.0047</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">G0</td><td align="left" colspan="1" rowspan="1">0.0734</td><td align="left" colspan="1" rowspan="1">0.1102</td><td align="left" colspan="1" rowspan="1">0.5094</td><td align="left" colspan="1" rowspan="1">0.6499</td></tr><tr><td align="left" colspan="1" rowspan="1">G1</td><td align="left" colspan="1" rowspan="1">0.0970</td><td align="left" colspan="1" rowspan="1">0.1574</td><td align="left" colspan="1" rowspan="1">0.5416</td><td align="left" colspan="1" rowspan="1">0.6499</td></tr><tr><td align="left" colspan="1" rowspan="1">G2</td><td align="left" colspan="1" rowspan="1">&#8722;0.1150</td><td align="left" colspan="1" rowspan="1">0.1022</td><td align="left" colspan="1" rowspan="1">0.2682</td><td align="left" colspan="1" rowspan="1">0.5364</td></tr><tr><td align="left" colspan="1" rowspan="1">S</td><td align="left" colspan="1" rowspan="1">0.0284</td><td align="left" colspan="1" rowspan="1">0.1191</td><td align="left" colspan="1" rowspan="1">0.8131</td><td align="left" colspan="1" rowspan="1">0.8131</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">B</italic> Bisected N-glycans, <italic toggle="yes">CF</italic> Core fucosylated N-glycans, <italic toggle="yes">G0</italic> Agalactosylated N-glycans, <italic toggle="yes">G1</italic> Monogalactosylated N-glycans, <italic toggle="yes">G2</italic> Digalactosylated N-glycans, <italic toggle="yes">S</italic> Sialylated N-glycans</p><p>[P&#8201;&lt;&#8201;0.05] &#8211; Bold</p></table-wrap-foot></table-wrap>
</p><p id="Par77">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Longitudinal changes in IgG glycosylation traits before and after treatment. Y-axis shows relative abundance values normalized to baseline. The bold lines represent the mean changes across patients. Each thin line represents an individual patient, color-coded by clinical response status. Dashed colored lines indicate mean changes within each response group, and the solid black line denotes the overall cohort mean change. B, bisected N-glycans; CF, core fucosylated N-glycans; G0, agalactosylated N-glycans; G1, monogalactosylated N-glycans; G2, digalactosylated N-glycans; S, sialylated N-glycans</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e979" position="float" orientation="portrait" xlink:href="12885_2025_15381_Fig1_HTML.jpg"/></fig>
</p><p id="Par78">While the overall longitudinal analysis revealed changes primarily in IgG core fucosylation, further stratification by chemotherapy regimen uncovered additional, treatment-specific glycosylation patterns (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>, Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). In patients receiving the ACdd regimen (<italic toggle="yes">n</italic>&#8201;=&#8201;22), core fucosylation (CF) and digalactosylation (G2) significantly decreased, whereas monogalactosylation (G1) increased (adjusted <italic toggle="yes">P</italic>&#8201;=&#8201;0.0476). The TC regimen (<italic toggle="yes">n</italic>&#8201;=&#8201;3) showed the most pronounced reduction in CF (adjusted <italic toggle="yes">P</italic>&#8201;=&#8201;0.0267). Additional shifts in sialylation, digalactosylation, and agalactosylation (G0) were observed in this group but did not reach statistical significance, likely due to the limited sample size. In the TCbHP group (<italic toggle="yes">n</italic>&#8201;=&#8201;9), a significant decrease in bisecting GlcNAc (B) was observed (adjusted <italic toggle="yes">P</italic>&#8201;=&#8201;0.0476), while other traits remained unchanged.</p><p id="Par79">Taken together, these results indicate that chemotherapy induces treatment-specific effects on IgG glycosylation, particularly in traits such as core fucosylation and bisecting GlcNAc, which may have functional implications for antibody-dependent cellular cytotoxicity (ADCC) and immune effector mechanisms.</p><p id="Par80">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Therapy-specific longitudinal changes in IgG glycosylation traits. Y-axis shows normalized relative abundance values. The bold lines represent the group&#8217;s means. B, bisected N-glycans; CF, core fucosylated N-glycans; G0, agalactosylated N-glycans; G1, monogalactosylated N-glycans; G2, digalactosylated N-glycans; S, sialylated N-glycans</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1018" position="float" orientation="portrait" xlink:href="12885_2025_15381_Fig2_HTML.jpg"/></fig>
</p><p id="Par81">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Therapy-specific changes in IgG glycan traits across two timepoints</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Therapy</th><th align="left" colspan="1" rowspan="1">Glycan Trait (IgG)</th><th align="left" colspan="1" rowspan="1">Time Effect (RANK)</th><th align="left" colspan="1" rowspan="1">Time Standard Error</th><th align="left" colspan="1" rowspan="1">Time&#160;<italic toggle="yes">P</italic>&#160;Value</th><th align="left" colspan="1" rowspan="1">Time-Adjusted&#160;<italic toggle="yes">P</italic>&#160;Value</th></tr></thead><tbody><tr><td align="left" rowspan="6" colspan="1">ACdd</td><td align="left" colspan="1" rowspan="1">B</td><td align="left" colspan="1" rowspan="1">0.0270</td><td align="left" colspan="1" rowspan="1">0.1402</td><td align="left" colspan="1" rowspan="1">0.8483</td><td align="left" colspan="1" rowspan="1">0.8483</td></tr><tr><td align="left" colspan="1" rowspan="1">CF</td><td align="left" colspan="1" rowspan="1">&#8722;0.2964</td><td align="left" colspan="1" rowspan="1">0.1099</td><td align="left" colspan="1" rowspan="1">
<bold>0.0103</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.0476</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">G0</td><td align="left" colspan="1" rowspan="1">0.1508</td><td align="left" colspan="1" rowspan="1">0.1289</td><td align="left" colspan="1" rowspan="1">0.2490</td><td align="left" colspan="1" rowspan="1">0.3735</td></tr><tr><td align="left" colspan="1" rowspan="1">G1</td><td align="left" colspan="1" rowspan="1">0.4489</td><td align="left" colspan="1" rowspan="1">0.1728</td><td align="left" colspan="1" rowspan="1">
<bold>0.0132</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.0476</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">G2</td><td align="left" colspan="1" rowspan="1">&#8722;0.3003</td><td align="left" colspan="1" rowspan="1">0.1143</td><td align="left" colspan="1" rowspan="1">
<bold>0.0123</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.0476</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">S</td><td align="left" colspan="1" rowspan="1">&#8722;0.1396</td><td align="left" colspan="1" rowspan="1">0.1388</td><td align="left" colspan="1" rowspan="1">0.3208</td><td align="left" colspan="1" rowspan="1">0.4442</td></tr><tr><td align="left" rowspan="6" colspan="1">TC</td><td align="left" colspan="1" rowspan="1">B</td><td align="left" colspan="1" rowspan="1">&#8722;0.2666</td><td align="left" colspan="1" rowspan="1">0.3768</td><td align="left" colspan="1" rowspan="1">0.4834</td><td align="left" colspan="1" rowspan="1">0.5801</td></tr><tr><td align="left" colspan="1" rowspan="1">CF</td><td align="left" colspan="1" rowspan="1">&#8722;1.0114</td><td align="left" colspan="1" rowspan="1">0.2958</td><td align="left" colspan="1" rowspan="1">
<bold>0.0015</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.0267</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">G0</td><td align="left" colspan="1" rowspan="1">&#8722;0.7650</td><td align="left" colspan="1" rowspan="1">0.3460</td><td align="left" colspan="1" rowspan="1">
<bold>0.0328</bold>
</td><td align="left" colspan="1" rowspan="1">0.0761</td></tr><tr><td align="left" colspan="1" rowspan="1">G1</td><td align="left" colspan="1" rowspan="1">&#8722;0.5887</td><td align="left" colspan="1" rowspan="1">0.4625</td><td align="left" colspan="1" rowspan="1">0.2103</td><td align="left" colspan="1" rowspan="1">0.3441</td></tr><tr><td align="left" colspan="1" rowspan="1">G2</td><td align="left" colspan="1" rowspan="1">0.6755</td><td align="left" colspan="1" rowspan="1">0.3073</td><td align="left" colspan="1" rowspan="1">
<bold>0.0338</bold>
</td><td align="left" colspan="1" rowspan="1">0.0761</td></tr><tr><td align="left" colspan="1" rowspan="1">S</td><td align="left" colspan="1" rowspan="1">0.9238</td><td align="left" colspan="1" rowspan="1">0.3727</td><td align="left" colspan="1" rowspan="1">
<bold>0.0175</bold>
</td><td align="left" colspan="1" rowspan="1">0.0526</td></tr><tr><td align="left" rowspan="6" colspan="1">TCbHP</td><td align="left" colspan="1" rowspan="1">B</td><td align="left" colspan="1" rowspan="1">&#8722;0.6193</td><td align="left" colspan="1" rowspan="1">0.2202</td><td align="left" colspan="1" rowspan="1">
<bold>0.0078</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.0476</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">CF</td><td align="left" colspan="1" rowspan="1">&#8722;0.2280</td><td align="left" colspan="1" rowspan="1">0.1723</td><td align="left" colspan="1" rowspan="1">0.1937</td><td align="left" colspan="1" rowspan="1">0.3441</td></tr><tr><td align="left" colspan="1" rowspan="1">G0</td><td align="left" colspan="1" rowspan="1">0.1737</td><td align="left" colspan="1" rowspan="1">0.2025</td><td align="left" colspan="1" rowspan="1">0.3965</td><td align="left" colspan="1" rowspan="1">0.5098</td></tr><tr><td align="left" colspan="1" rowspan="1">G1</td><td align="left" colspan="1" rowspan="1">&#8722;0.5313</td><td align="left" colspan="1" rowspan="1">0.2723</td><td align="left" colspan="1" rowspan="1">0.0586</td><td align="left" colspan="1" rowspan="1">0.1171</td></tr><tr><td align="left" colspan="1" rowspan="1">G2</td><td align="left" colspan="1" rowspan="1">0.0736</td><td align="left" colspan="1" rowspan="1">0.1795</td><td align="left" colspan="1" rowspan="1">0.6840</td><td align="left" colspan="1" rowspan="1">0.7243</td></tr><tr><td align="left" colspan="1" rowspan="1">S</td><td align="left" colspan="1" rowspan="1">0.1334</td><td align="left" colspan="1" rowspan="1">0.2181</td><td align="left" colspan="1" rowspan="1">0.5444</td><td align="left" colspan="1" rowspan="1">0.6124</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">B</italic> Bisected N-glycans, <italic toggle="yes">CF</italic> Core fucosylated N-glycans, <italic toggle="yes">G0</italic> Agalactosylated N-glycans, <italic toggle="yes">G1</italic> Monogalactosylated N-glycans, <italic toggle="yes">G2</italic> Digalactosylated N-glycans, <italic toggle="yes">S</italic> Sialylated N-glycans, <italic toggle="yes">ACdd</italic> Doxorubicin, cyclophosphamide dose-dense therapy, <italic toggle="yes">TCbHP</italic> Docetaxel, carboplatin, trastuzumab and pertuzumab therapy, <italic toggle="yes">TC</italic> Docetaxel&#8201;+&#8201;cyclophosphamide</p><p>[P&#8201;&lt;&#8201;0.05] &#8211; Bold</p></table-wrap-foot></table-wrap>
</p><p id="Par82">To assess the robustness of these therapy-specific findings, a post hoc power analysis was conducted across the derived IgG traits, given the small and unbalanced group sizes (22/3/9 paired samples). The observed effects between treatment regimens were moderate to large (Cohen&#8217;s f&#8201;=&#8201;0.43&#8211;0.61). However, due to unequal group sizes, the achieved power was modest (0.30&#8211;0.55; median 0.34). Even for the largest effect (G1, f&#8201;=&#8201;0.61), statistical power remained below the conventional 0.80 threshold.</p><p id="Par83">In contrast to these IgG-specific alterations, the derived glycosylation traits of total plasma proteins remained largely stable across timepoints. The only notable exception was an increase in oligomannose glycans following chemotherapy (adjusted <italic toggle="yes">P</italic>&#8201;=&#8201;0.0253; Supplementary Table 3, Supplementary Fig.&#160;2). Trend toward increased oligomannosylation was noted in the ACdd group (Supplementary Table 4) and partial responders (Supplementary Table 5) but did not reach statistical significance.</p><p id="Par84">To further explore the biological relevance of plasma glycosylation, we examined associations with clinical tumor size. Exploratory analysis revealed a strong association between tumor size and plasma-derived glycan traits. Due to sample size limitations, direct pairwise comparisons were not feasible; instead, tumor size was evaluated as a predictor in a linear mixed-effects model (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Among the 16 plasma-derived glycan traits, 9 were significantly associated with tumor size. The most pronounced changes were observed in digalactosylation (G2_p) and oligomannosylation (Man), particularly among patients with large or advanced tumors (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). The largest shift in glycosylation profiles occurred between intermediate-sized and advanced tumors, suggesting that tumor burden may substantially influence systemic glycan composition.</p><p id="Par85">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Plasma glycosylation profiles stratified by clinical tumor stage. Error bars indicate 95% confidence intervals. Tumor stages: In situ (&lt;&#8201;1&#160;mm), small (1&#8211;10&#160;mm), intermediate (10&#8211;50&#160;mm), and large (&gt;&#8201;50&#160;mm or advanced). The right panel shows Benjamini&#8211;Hochberg&#8211;corrected P values from ANOVA testing the effect of tumor size. LB, low branching; HB, high branching; S0&#8211;S4, increasing sialylation; G0_p&#8211;G4, increasing galactosylation; Man, oligomannose N-glycans; B_p, bisected N-glycans; CF_p, core fucosylated N-glycans; AF, antennary fucosylated N-glycans</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1370" position="float" orientation="portrait" xlink:href="12885_2025_15381_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec17"><title>Discussion</title><p id="Par86">Despite major advances in breast cancer diagnostics and therapy, the lack of sensitive, minimally invasive biomarkers for real-time monitoring remains a critical gap in clinical care. Current tools, such as serum markers (e.g., CA 15&#8201;&#8722;&#8201;3, CEA) and imaging, have limitations in terms of sensitivity, specificity, and timing. Our study provides novel evidence that N-glycosylation of immunoglobulin G (IgG) and total plasma proteins reflect therapeutic effects and indicate that further studies may provide a better understanding of its potential as a useful biomarker for breast cancer.</p><p id="Par87">The most consistent finding across all therapy types was a significant decrease in IgG core fucosylation following neoadjuvant chemotherapy. Given the known role of afucosylated IgG in enhancing antibody-dependent cellular cytotoxicity (ADCC) via increased Fc&#947;RIIIa binding [<xref ref-type="bibr" rid="CR33">33</xref>], this observation may reflect an immunological shift that enhances antitumor immunity. This is particularly relevant in regimens that include taxanes and HER2-targeted therapies such as trastuzumab, both of which have been shown to modulate NK cell-mediated cytotoxicity and amplify ADCC responses [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. The decline in core fucosylation we observed might therefore reflect a shift toward a more ADCC-permissive IgG repertoire, providing indirect insight into immune activation during treatment.</p><p id="Par88">Therapy-specific glycan shifts were also observed. TC therapy was associated only with decreased core fucosylation, whereas ACdd was additionally associated with decreased digalactosylation and increased monogalactosylation. TCbHP treatment uniquely decreased the level of bisecting GlcNAc. These patterns likely reflect both direct effects of chemotherapy and immunomodulatory interactions. These patterns are consistent with prior reports showing that systemic therapies induce distinct glycomic signatures: for example, endocrine therapies such as tamoxifen and anastrozole differentially modulate IgG glycosylation in luminal breast cancer [<xref ref-type="bibr" rid="CR29">29</xref>]. Collectively, these results support the concept that systemic therapy imprints a distinct glycomic &#8220;fingerprint&#8221; on the IgG pool.</p><p id="Par89">By contrast, the total plasma N-glycome was largely stable in our study, with one clear exception: an increase in oligomannose glycans. This observation is consistent with earlier N-glycomic studies on total plasma proteins in breast cancer, which reported therapy-associated changes in global glycosylation patterns [<xref ref-type="bibr" rid="CR20">20</xref>]. Importantly, a recent meta-analysis confirmed that oligomannose glycans are elevated across multiple human cancers, including breast cancer, and linked this to altered &#945;1,2-mannosidase activity [<xref ref-type="bibr" rid="CR36">36</xref>]. Similarly, de Leoz et al. showed that oligomannose glycans increase during breast cancer progression in a transgenic mouse model and in patient sera [<xref ref-type="bibr" rid="CR22">22</xref>]. &#352;&#269;up&#225;kov&#225; et al. extended this finding to human metastases, where metastatic lesions exhibited enrichment in oligomannose glycans and downregulation of mannose-trimming enzymes [<xref ref-type="bibr" rid="CR37">37</xref>]. Consistent with these systemic changes, Choi et al. demonstrated that both the serum levels and glycosylation of alpha-1-acid glycoprotein vary with breast cancer severity, underscoring that individual acute-phase proteins contribute to the altered plasma glycome and may carry stage-relevant glycosylation signatures [<xref ref-type="bibr" rid="CR38">38</xref>]. Together with our observation that oligomannose glycans correlated with tumor size, these studies support the idea that plasma oligomannosylation may serve as a surrogate for tumor burden and altered glycan-processing pathways.</p><p id="Par90">Importantly, the strength of the glycosylation&#8211;tumor size correlation, even in a modest sample, suggests the potential for glycan traits as biomarkers of disease progression. Interestingly, patients with large or advanced tumors presented glycan profiles resembling those of patients with in situ disease, suggesting nonlinear or subtype-specific associations that merit further investigation.</p><p id="Par91">Beyond systemic biomarkers, aberrant N-glycosylation also has mechanistic implications in tumor biology. For example, site-specific N-glycosylation of CD24 is required for its stable cell-surface localization in basal breast cancer, influencing adhesion and immune interactions [<xref ref-type="bibr" rid="CR39">39</xref>]. Aberrant glycosylation of receptors such as EGFR and integrins similarly alters signaling, migration, and therapy response [<xref ref-type="bibr" rid="CR40">40</xref>]. Thus, plasma glycome may be understood not only as a composite biomarker but also as a systemic mirror of tumor-intrinsic glycoprotein remodeling.</p><p id="Par92">The strengths of this study include its longitudinal design, the use of high-throughput, robust glycomic methods, and therapy-stratified analysis. However, several limitations must be acknowledged. First, the single-center design and small sample size (<italic toggle="yes">n</italic>&#8201;=&#8201;34) limit generalizability and statistical power, particularly for subgroup comparisons. Second, the absence of a healthy control group restricts our ability to draw diagnostic conclusions. Third, while plasma glycomics provide a global snapshot of systemic glycosylation, it lacks resolution at the protein carrier and site-specific level; thus, disease-relevant changes in individual glycoproteins may be masked within the composite plasma glycome. Future studies should validate these findings in larger, multi-institutional cohorts with long-term follow-up and survival endpoints. Integrating glycan profiling into multiomic liquid biopsy approaches may also increase its utility in clinical workflows.</p><p id="Par93">In summary, our findings demonstrate that IgG N-glycosylation, particularly core fucosylation, is modulated by chemotherapy and varies with treatment regimen. At the same time, plasma oligomannose glycans correlate with tumor size, in line with previous reports across breast and other cancers. These glycomic signatures may offer a minimally invasive, immunologically relevant tool to monitor treatment efficacy and disease progression, with potential applications in precision oncology. However, future studies are warranted to investigate their biomarker potential in greater depth.</p></sec><sec id="Sec18"><title>Conclusions</title><p id="Par94">This study demonstrates that IgG N-glycosylation is dynamically remodeled by neoadjuvant chemotherapy in a regimen-specific manner, with consistent decreases in core fucosylation and additional shifts in galactosylation and bisecting GlcNAc. These alterations are not only markers of therapy response but may also reflect enhanced antibody effector functions, including increased ADCC. In contrast, the total plasma N-glycome remained largely stable, with the notable exception of elevated oligomannose glycans, which correlated with tumor size and likely mirror altered glycan processing pathways in cancer. Together, these findings indicate that IgG and plasma glycomic traits capture both immune modulation and tumor burden. Glycan profiling, particularly of IgG, holds promise as a minimally invasive biomarker for monitoring treatment response and may support more personalized therapeutic strategies in breast cancer which should be validated in future studies.</p></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12885_2025_15381_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACdd</term><def><p id="Par5">Doxorubicin and cyclophosphamide dose-dense therapy</p></def></def-item><def-item><term>ADCC</term><def><p id="Par6">Antibody-dependent cellular cytotoxicity</p></def></def-item><def-item><term>AJCC/UICC</term><def><p id="Par7">American Joint Committee on Cancer/Union for International Cancer</p></def></def-item><def-item><term>ATM</term><def><p id="Par8">Ataxia Telangiectasia Mutated gene</p></def></def-item><def-item><term>B</term><def><p id="Par9">Bisected N-glycans</p></def></def-item><def-item><term>BMI</term><def><p id="Par10">Body Mass Index</p></def></def-item><def-item><term>BRCA1</term><def><p id="Par11">Breast Cancer Gene 1</p></def></def-item><def-item><term>BRCA2</term><def><p id="Par12">Breast Cancer Gene 2</p></def></def-item><def-item><term>CA 15&#8201;&#8722;&#8201;3</term><def><p id="Par13">Cancer Antigen 15&#8201;&#8722;&#8201;3</p></def></def-item><def-item><term>CBC</term><def><p id="Par14">Complete Blood Count</p></def></def-item><def-item><term>CHEK2</term><def><p id="Par15">Checkpoint Kinase 2</p></def></def-item><def-item><term>CF</term><def><p id="Par16">Core fucosylation</p></def></def-item><def-item><term>CR</term><def><p id="Par17">Complete Response</p></def></def-item><def-item><term>CT</term><def><p id="Par18">Computed Tomography</p></def></def-item><def-item><term>DCIS</term><def><p id="Par19">Ductal Carcinoma In Situ</p></def></def-item><def-item><term>DMSO</term><def><p id="Par20">Dimethyl Sulfoxide</p></def></def-item><def-item><term>EDTA</term><def><p id="Par21">Ethylenediaminetetraacetic acid</p></def></def-item><def-item><term>ER</term><def><p id="Par22">Estrogen Receptor</p></def></def-item><def-item><term>G</term><def><p id="Par23">Galactosylation (general)</p></def></def-item><def-item><term>G0</term><def><p id="Par24">Agalactosylated N-glycans</p></def></def-item><def-item><term>G1</term><def><p id="Par25">Monogalactosylated N-glycans</p></def></def-item><def-item><term>G2</term><def><p id="Par26">Digalactosylated N-glycans</p></def></def-item><def-item><term>GP</term><def><p id="Par27">Glycan Peak</p></def></def-item><def-item><term>HER2</term><def><p id="Par28">Human Epidermal Growth Factor Receptor 2</p></def></def-item><def-item><term>IgG</term><def><p id="Par29">Immunoglobulin G</p></def></def-item><def-item><term>Ki67</term><def><p id="Par30">Proliferation marker Ki67</p></def></def-item><def-item><term>MINDACT</term><def><p id="Par31">Microarray in Node-Negative Disease May Avoid Chemotherapy trial</p></def></def-item><def-item><term>MRI</term><def><p id="Par32">Magnetic Resonance Imaging</p></def></def-item><def-item><term>NK</term><def><p id="Par33">Natural Killer cells</p></def></def-item><def-item><term>NST</term><def><p id="Par34">No Special Type (histological subtype of breast cancer)</p></def></def-item><def-item><term>PBS</term><def><p id="Par35">Phosphate Buffered Saline</p></def></def-item><def-item><term>PET/CT</term><def><p id="Par36">Positron Emission Tomography/Computed Tomography</p></def></def-item><def-item><term>PALB2</term><def><p id="Par37">Partner and Localizer of BRCA2</p></def></def-item><def-item><term>PR</term><def><p id="Par38">Partial Response or Progesterone Receptor (depending on context)</p></def></def-item><def-item><term>PTEN</term><def><p id="Par39">Phosphatase and Tensin Homolog</p></def></def-item><def-item><term>S</term><def><p id="Par40">Sialylation</p></def></def-item><def-item><term>S1</term><def><p id="Par41">Monosialylated N-glycans</p></def></def-item><def-item><term>S2</term><def><p id="Par42">Disialylated N-glycans</p></def></def-item><def-item><term>SDS</term><def><p id="Par43">Sodium Dodecyl Sulfate</p></def></def-item><def-item><term>SPE</term><def><p id="Par44">Solid-Phase Extraction</p></def></def-item><def-item><term>TAILORx</term><def><p id="Par45">Trial Assigning Individualized Options for Treatment Rx</p></def></def-item><def-item><term>TC</term><def><p id="Par46">Docetaxel and Cyclophosphamide therapy</p></def></def-item><def-item><term>TCbHP</term><def><p id="Par47">Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab</p></def></def-item><def-item><term>TP53</term><def><p id="Par48">Tumor Protein p53</p></def></def-item><def-item><term>2-AB</term><def><p id="Par49">2-Aminobenzamide</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Martina Mari&#269;i&#263; Vrban and Barbara Radovani Trbojevi&#263; contributed equally.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank the clinical and laboratory staff at the University Hospital for Tumors, Sestre milosrdnice Clinical Hospital Center, and the collaborators from St. Catherine Hospital, the International Society for Applied Biological Sciences, and the International Center for Applied Biological Sciences for their support.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>IG, DP and GL contributed to the conception and design of the study, supervised the clinical protocol, and critically revised the manuscript. MMV, IK, MG and IM collected clinical data, coordinated patient recruitment, and contributed to interpretation of clinical outcomes. BRT and KR performed laboratory experiments and data acquisition related to glycan profiling. DV conducted statistical analysis and contributed to the interpretation of glycomic data. MMV, BRT and DV drafted the manuscript and created figures and tables with input from all authors. All authors reviewed and approved the final version of the manuscript. They agree to be personally accountable for their individual contributions and to ensure the integrity and accuracy of the work is appropriately investigated and resolved.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by the Horizon Europe program (grant No. 101159018, SynHealth).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The UHPLC glycomic datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par95">The study was approved by the Ethics Committee of the University Hospital for Tumors, Sestre milosrdnice Clinical Hospital Center, Zagreb, Croatia. All participants provided written informed consent prior to inclusion in the study. The study was conducted in accordance with the Declaration of Helsinki.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par96">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par97">GL declares that he is the founder and owner of Genos Glycoscience Research Laboratory, which offers commercial services of glycomic analysis and has several patents in this field. IG and BRT are employees of Genos Glycoscience Research Laboratory. The other authors declare no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giaquinto</surname><given-names>AN</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Newman</surname><given-names>LA</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>RA</given-names></name><name name-style="western"><surname>Smith</surname><given-names>RA</given-names></name><name name-style="western"><surname>Star</surname><given-names>J</given-names></name><etal/></person-group><article-title>Breast cancer statistics 2024</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><fpage>477</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.3322/caac.21863</pub-id><pub-id pub-id-type="pmid">39352042</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477&#8211;95. 10.3322/caac.21863.<pub-id pub-id-type="pmid">39352042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21863</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><etal/></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><fpage>229</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229&#8211;63. 10.3322/caac.21834.<pub-id pub-id-type="pmid">38572751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>PH</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>I</given-names></name><name name-style="western"><surname>Allison</surname><given-names>K</given-names></name><name name-style="western"><surname>Brogi</surname><given-names>E</given-names></name><name name-style="western"><surname>Fox</surname><given-names>SB</given-names></name><name name-style="western"><surname>Lakhani</surname><given-names>S</given-names></name><etal/></person-group><article-title>The 2019 world health organization classification of tumours of the breast</article-title><source>Histopathology</source><year>2020</year><volume>77</volume><fpage>181</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1111/his.14091</pub-id><pub-id pub-id-type="pmid">32056259</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 world health organization classification of tumours of the breast. Histopathology. 2020;77:181&#8211;5. 10.1111/his.14091.<pub-id pub-id-type="pmid">32056259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/his.14091</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lima</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kehm</surname><given-names>RD</given-names></name><name name-style="western"><surname>Terry</surname><given-names>MB</given-names></name></person-group><article-title>Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns</article-title><source>EClinicalMedicine</source><year>2021</year><volume>38</volume><fpage>100985</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2021.100985</pub-id><pub-id pub-id-type="pmid">34278281</pub-id><pub-id pub-id-type="pmcid">PMC8271114</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Lima SM, Kehm RD, Terry MB. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine. 2021;38:100985. 10.1016/j.eclinm.2021.100985.<pub-id pub-id-type="pmid">34278281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2021.100985</pub-id><pub-id pub-id-type="pmcid">PMC8271114</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beral</surname><given-names>V</given-names></name></person-group><article-title>Breast cancer and hormone-replacement therapy in the million women study</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>419</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)14065-2</pub-id><pub-id pub-id-type="pmid">12927427</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet. 2003;362:419&#8211;27. 10.1016/S0140-6736(03)14065-2.<pub-id pub-id-type="pmid">12927427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(03)14065-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><collab>Breast cancer and hormone</collab></person-group><article-title>Replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer</article-title><source>Lancet</source><year>1997</year><volume>350</volume><fpage>1047</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(97)08233-0</pub-id><pub-id pub-id-type="pmid">10213546</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Breast cancer and hormone. Replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997;350:1047&#8211;59. 10.1016/S0140-6736(97)08233-0.<pub-id pub-id-type="pmid">10213546</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>Update on prognostic and predictive biomarkers of breast cancer</article-title><source>Semin Diagn Pathol</source><year>2022</year><volume>39</volume><fpage>322</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1053/j.semdp.2022.06.015</pub-id><pub-id pub-id-type="pmid">35752515</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Hou Y, Peng Y, Li Z. Update on prognostic and predictive biomarkers of breast cancer. Semin Diagn Pathol. 2022;39:322&#8211;32. 10.1053/j.semdp.2022.06.015.<pub-id pub-id-type="pmid">35752515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.semdp.2022.06.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harbeck</surname><given-names>N</given-names></name><name name-style="western"><surname>Penault-Llorca</surname><given-names>F</given-names></name><name name-style="western"><surname>Cortes</surname><given-names>J</given-names></name><name name-style="western"><surname>Gnant</surname><given-names>M</given-names></name><name name-style="western"><surname>Houssami</surname><given-names>N</given-names></name><name name-style="western"><surname>Poortmans</surname><given-names>P</given-names></name><etal/></person-group><article-title>Breast cancer</article-title><source>Nat Rev Dis Primers</source><year>2019</year><volume>5</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.1038/s41572-019-0111-2</pub-id><pub-id pub-id-type="pmid">31548545</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:66. 10.1038/s41572-019-0111-2.<pub-id pub-id-type="pmid">31548545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-019-0111-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabatier</surname><given-names>R</given-names></name><name name-style="western"><surname>Gon&#231;alves</surname><given-names>A</given-names></name><name name-style="western"><surname>Bertucci</surname><given-names>F</given-names></name></person-group><article-title>Personalized medicine: present and future of breast cancer management</article-title><source>Crit Rev Oncol Hematol</source><year>2014</year><volume>91</volume><fpage>223</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2014.03.002</pub-id><pub-id pub-id-type="pmid">24725667</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Sabatier R, Gon&#231;alves A, Bertucci F. Personalized medicine: present and future of breast cancer management. Crit Rev Oncol Hematol. 2014;91:223&#8211;33. 10.1016/j.critrevonc.2014.03.002.<pub-id pub-id-type="pmid">24725667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2014.03.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Dai</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name></person-group><article-title>Clinicopathological and prognostic significance of cancer antigen 15&#8201;&#8211;&#8201;3 and carcinoembryonic antigen in breast cancer: a meta-analysis including 12,993 patients</article-title><source>Dis Markers</source><year>2018</year><volume>2018</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1155/2018/9863092</pub-id><pub-id pub-id-type="pmcid">PMC5954898</pub-id><pub-id pub-id-type="pmid">29854028</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Li X, Dai D, Chen B, Tang H, Xie X, Wei W. Clinicopathological and prognostic significance of cancer antigen 15&#8201;&#8211;&#8201;3 and carcinoembryonic antigen in breast cancer: a meta-analysis including 12,993 patients. Dis Markers. 2018;2018:1&#8211;15. 10.1155/2018/9863092.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2018/9863092</pub-id><pub-id pub-id-type="pmcid">PMC5954898</pub-id><pub-id pub-id-type="pmid">29854028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>EW</given-names></name><name name-style="western"><surname>Crown</surname><given-names>J</given-names></name></person-group><article-title>Blood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating tumor DNA</article-title><source>Tumor Biol</source><year>2018</year><volume>40</volume><fpage>101042831877616</fpage><pub-id pub-id-type="doi">10.1177/1010428318776169</pub-id><pub-id pub-id-type="pmid">29775157</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Duffy MJ, McDermott EW, Crown J. Blood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating tumor DNA. Tumor Biol. 2018;40:101042831877616. 10.1177/1010428318776169.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1010428318776169</pub-id><pub-id pub-id-type="pmid">29775157</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kataja</surname><given-names>V</given-names></name><name name-style="western"><surname>Castiglione</surname><given-names>M</given-names></name></person-group><article-title>Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2009</year><volume>20</volume><fpage>iv10</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdp114</pub-id><pub-id pub-id-type="pmid">19454421</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Kataja V, Castiglione M. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:iv10&#8211;4. 10.1093/annonc/mdp114.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdp114</pub-id><pub-id pub-id-type="pmid">19454421</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loibl</surname><given-names>S</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>F</given-names></name><name name-style="western"><surname>Bachelot</surname><given-names>T</given-names></name><name name-style="western"><surname>Barrios</surname><given-names>CH</given-names></name><name name-style="western"><surname>Bergh</surname><given-names>J</given-names></name><name name-style="western"><surname>Burstein</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2024</year><volume>35</volume><fpage>159</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2023.11.016</pub-id><pub-id pub-id-type="pmid">38101773</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Loibl S, Andr&#233; F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159&#8211;82. 10.1016/j.annonc.2023.11.016.<pub-id pub-id-type="pmid">38101773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2023.11.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reily</surname><given-names>C</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Renfrow</surname><given-names>MB</given-names></name><name name-style="western"><surname>Novak</surname><given-names>J</given-names></name></person-group><article-title>Glycosylation in health and disease</article-title><source>Nat Rev Nephrol</source><year>2019</year><volume>15</volume><fpage>346</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/s41581-019-0129-4</pub-id><pub-id pub-id-type="pmid">30858582</pub-id><pub-id pub-id-type="pmcid">PMC6590709</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019;15:346&#8211;66. 10.1038/s41581-019-0129-4.<pub-id pub-id-type="pmid">30858582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-019-0129-4</pub-id><pub-id pub-id-type="pmcid">PMC6590709</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>DA</given-names></name><name name-style="western"><surname>Drake</surname><given-names>RR</given-names></name></person-group><article-title>Glycosylation and its implications in breast cancer</article-title><source>Expert Rev Proteomics</source><year>2019</year><volume>16</volume><fpage>665</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1080/14789450.2019.1645604</pub-id><pub-id pub-id-type="pmid">31314995</pub-id><pub-id pub-id-type="pmcid">PMC6702063</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Scott DA, Drake RR. Glycosylation and its implications in breast cancer. Expert Rev Proteomics. 2019;16:665&#8211;80. 10.1080/14789450.2019.1645604.<pub-id pub-id-type="pmid">31314995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14789450.2019.1645604</pub-id><pub-id pub-id-type="pmcid">PMC6702063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peric</surname><given-names>L</given-names></name><name name-style="western"><surname>Vukadin</surname><given-names>S</given-names></name><name name-style="western"><surname>Petrovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Kuna</surname><given-names>L</given-names></name><name name-style="western"><surname>Puseljic</surname><given-names>N</given-names></name><name name-style="western"><surname>Sikora</surname><given-names>R</given-names></name><etal/></person-group><article-title>Glycosylation alterations in cancer cells, prognostic value of glycan biomarkers and their potential as novel therapeutic targets in breast cancer</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><fpage>3265</fpage><pub-id pub-id-type="doi">10.3390/biomedicines10123265</pub-id><pub-id pub-id-type="pmid">36552021</pub-id><pub-id pub-id-type="pmcid">PMC9775348</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Peric L, Vukadin S, Petrovic A, Kuna L, Puseljic N, Sikora R, et al. Glycosylation alterations in cancer cells, prognostic value of glycan biomarkers and their potential as novel therapeutic targets in breast cancer. Biomedicines. 2022;10:3265. 10.3390/biomedicines10123265.<pub-id pub-id-type="pmid">36552021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines10123265</pub-id><pub-id pub-id-type="pmcid">PMC9775348</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vreeker</surname><given-names>GCM</given-names></name><name name-style="western"><surname>Vangangelt</surname><given-names>KMH</given-names></name><name name-style="western"><surname>Bladergroen</surname><given-names>MR</given-names></name><name name-style="western"><surname>Nicolardi</surname><given-names>S</given-names></name><name name-style="western"><surname>Mesker</surname><given-names>WE</given-names></name><name name-style="western"><surname>Wuhrer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Serum N-glycan profiles differ for various breast cancer subtypes</article-title><source>Glycoconj J</source><year>2021</year><volume>38</volume><fpage>387</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s10719-021-10001-3</pub-id><pub-id pub-id-type="pmid">33877489</pub-id><pub-id pub-id-type="pmcid">PMC8116229</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Vreeker GCM, Vangangelt KMH, Bladergroen MR, Nicolardi S, Mesker WE, Wuhrer M, et al. Serum N-glycan profiles differ for various breast cancer subtypes. Glycoconj J. 2021;38:387&#8211;95. 10.1007/s10719-021-10001-3.<pub-id pub-id-type="pmid">33877489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10719-021-10001-3</pub-id><pub-id pub-id-type="pmcid">PMC8116229</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benesova</surname><given-names>I</given-names></name><name name-style="western"><surname>Nenutil</surname><given-names>R</given-names></name><name name-style="western"><surname>Urminsky</surname><given-names>A</given-names></name><name name-style="western"><surname>Lattova</surname><given-names>E</given-names></name><name name-style="western"><surname>Uhrik</surname><given-names>L</given-names></name><name name-style="western"><surname>Grell</surname><given-names>P</given-names></name><etal/></person-group><article-title>N-glycan profiling of tissue samples to aid breast cancer subtyping</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><fpage>320</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-51021-3</pub-id><pub-id pub-id-type="pmid">38172220</pub-id><pub-id pub-id-type="pmcid">PMC10764792</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Benesova I, Nenutil R, Urminsky A, Lattova E, Uhrik L, Grell P, et al. N-glycan profiling of tissue samples to aid breast cancer subtyping. Sci Rep. 2024;14:320. 10.1038/s41598-023-51021-3.<pub-id pub-id-type="pmid">38172220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-51021-3</pub-id><pub-id pub-id-type="pmcid">PMC10764792</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobie</surname><given-names>C</given-names></name><name name-style="western"><surname>Skropeta</surname><given-names>D</given-names></name></person-group><article-title>Insights into the role of sialylation in cancer progression and metastasis</article-title><source>Br J Cancer</source><year>2021</year><volume>124</volume><fpage>76</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/s41416-020-01126-7</pub-id><pub-id pub-id-type="pmid">33144696</pub-id><pub-id pub-id-type="pmcid">PMC7782833</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. Br J Cancer. 2021;124:76&#8211;90. 10.1038/s41416-020-01126-7.<pub-id pub-id-type="pmid">33144696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41416-020-01126-7</pub-id><pub-id pub-id-type="pmcid">PMC7782833</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saldova</surname><given-names>R</given-names></name><name name-style="western"><surname>Haakensen</surname><given-names>VD</given-names></name><name name-style="western"><surname>R&#248;dland</surname><given-names>E</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>I</given-names></name><name name-style="western"><surname>St&#246;ckmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Engebraaten</surname><given-names>O</given-names></name></person-group><article-title>Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up</article-title><source>Mol Oncol</source><year>2017</year><pub-id pub-id-type="doi">10.1002/1878-0261.12105</pub-id><pub-id pub-id-type="pmid">28657165</pub-id><pub-id pub-id-type="pmcid">PMC5623820</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Saldova R, Haakensen VD, R&#248;dland E, Walsh I, St&#246;ckmann H, Engebraaten O. Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up. Mol Oncol. 2017. 10.1002/1878-0261.12105.<pub-id pub-id-type="pmid">28657165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1878-0261.12105</pub-id><pub-id pub-id-type="pmcid">PMC5623820</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saldova</surname><given-names>R</given-names></name><name name-style="western"><surname>Reuben</surname><given-names>JM</given-names></name><name name-style="western"><surname>Abd Hamid</surname><given-names>UM</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>PM</given-names></name><name name-style="western"><surname>Cristofanilli</surname><given-names>M</given-names></name></person-group><article-title>Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts</article-title><source>Ann Oncol</source><year>2011</year><volume>22</volume><fpage>1113</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq570</pub-id><pub-id pub-id-type="pmid">21127012</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Saldova R, Reuben JM, Abd Hamid UM, Rudd PM, Cristofanilli M. Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. Ann Oncol. 2011;22:1113&#8211;9. 10.1093/annonc/mdq570.<pub-id pub-id-type="pmid">21127012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdq570</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">De Leoz MLA, Young LJT, An HJ, Kronewitter SR, Kim J, Miyamoto S, et al. High-Mannose glycans are elevated during. Breast Cancer Progression Mol Cell Proteom. 2010. 10.1074/mcp.M110.002717.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/mcp.M110.002717</pub-id><pub-id pub-id-type="pmcid">PMC3013453</pub-id><pub-id pub-id-type="pmid">21097542</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saldova</surname><given-names>R</given-names></name><name name-style="western"><surname>Shehni</surname><given-names>AA</given-names></name><name name-style="western"><surname>Haakensen</surname><given-names>VD</given-names></name><name name-style="western"><surname>Steinfeld</surname><given-names>I</given-names></name><name name-style="western"><surname>Hilliard</surname><given-names>M</given-names></name><name name-style="western"><surname>Kifer</surname><given-names>I</given-names></name><etal/></person-group><article-title>Association of N&#8211;glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC</article-title><source>J Proteome Res</source><year>2014</year><volume>13</volume><fpage>2314</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1021/pr401092y</pub-id><pub-id pub-id-type="pmid">24669823</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Saldova R, Shehni AA, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, et al. Association of N&#8211;glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC. J Proteome Res. 2014;13:2314&#8211;27. 10.1021/pr401092y.<pub-id pub-id-type="pmid">24669823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/pr401092y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Qiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>Development and validation of a model and nomogram for breast cancer diagnosis based on quantitative analysis of serum disease&#8209;specific haptoglobin N&#8209;glycosylation</article-title><source>J Transl Med</source><year>2024</year><volume>22</volume><fpage>331</fpage><pub-id pub-id-type="doi">10.1186/s12967-024-05039-4</pub-id><pub-id pub-id-type="pmid">38575942</pub-id><pub-id pub-id-type="pmcid">PMC10993522</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Li L, Xu Y, Lai Z, Li D, Qiang S, Li Z, et al. Development and validation of a model and nomogram for breast cancer diagnosis based on quantitative analysis of serum disease&#8209;specific haptoglobin N&#8209;glycosylation. J Transl Med. 2024;22:331. 10.1186/s12967-024-05039-4.<pub-id pub-id-type="pmid">38575942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-024-05039-4</pub-id><pub-id pub-id-type="pmcid">PMC10993522</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawaguchi-Sakita</surname><given-names>N</given-names></name><name name-style="western"><surname>Kaneshiro-Nakagawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>M</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Tokiwa</surname><given-names>M</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>E</given-names></name><etal/></person-group><article-title>Serum Immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls</article-title><source>Biochem Biophys Res Commun</source><year>2015</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2015.12.114</pub-id><pub-id pub-id-type="pmid">26740182</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Kawaguchi-Sakita N, Kaneshiro-Nakagawa K, Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, et al. Serum Immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. Biochem Biophys Res Commun. 2015. 10.1016/j.bbrc.2015.12.114.<pub-id pub-id-type="pmid">26740182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2015.12.114</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebrehiwot</surname><given-names>AG</given-names></name><name name-style="western"><surname>Melka</surname><given-names>DS</given-names></name><name name-style="western"><surname>Kassaye</surname><given-names>YM</given-names></name><name name-style="western"><surname>Gemechu</surname><given-names>T</given-names></name><name name-style="western"><surname>Lako</surname><given-names>W</given-names></name><name name-style="western"><surname>Hinou</surname><given-names>H</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>S-I</given-names></name></person-group><article-title>Exploring serum and Immunoglobulin G N-glycome as diagnsotic biomarkers for early detection of breast cancer in Ethiopian women</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><fpage>588</fpage><pub-id pub-id-type="doi">10.1186/s12885-019-5817-8</pub-id><pub-id pub-id-type="pmid">31208374</pub-id><pub-id pub-id-type="pmcid">PMC6580580</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Gebrehiwot AG, Melka DS, Kassaye YM, Gemechu T, Lako W, Hinou H, Nishimura S-I. Exploring serum and Immunoglobulin G N-glycome as diagnsotic biomarkers for early detection of breast cancer in Ethiopian women. BMC Cancer. 2019;19:588. 10.1186/s12885-019-5817-8.<pub-id pub-id-type="pmid">31208374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12885-019-5817-8</pub-id><pub-id pub-id-type="pmcid">PMC6580580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Haslund-Gourley BS, Wigdahl B, Comunale MA. IgG N-glycan signatures as potential diagnostic and prognostic biomarkers. Diagnostics 2023;13:1016.&#160;10.1186/s12885-019-5817-8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics13061016</pub-id><pub-id pub-id-type="pmcid">PMC10047871</pub-id><pub-id pub-id-type="pmid">36980324</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radovani</surname><given-names>B</given-names></name><name name-style="western"><surname>Nimmerjahn</surname><given-names>F</given-names></name></person-group><article-title>IgG glycosylation: biomarker, functional modulator, and structural component</article-title><source>J Immunol</source><year>2024</year><volume>213</volume><fpage>1573</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2400447</pub-id><pub-id pub-id-type="pmid">39556784</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Radovani B, Nimmerjahn F. IgG glycosylation: biomarker, functional modulator, and structural component. J Immunol. 2024;213:1573&#8211;84. 10.4049/jimmunol.2400447.<pub-id pub-id-type="pmid">39556784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.2400447</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rap&#269;an</surname><given-names>B</given-names></name><name name-style="western"><surname>Fan&#269;ovi&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Pribi&#263;</surname><given-names>T</given-names></name><name name-style="western"><surname>Kirac</surname><given-names>I</given-names></name><name name-style="western"><surname>Ga&#263;e</surname><given-names>M</given-names></name><name name-style="western"><surname>Vu&#269;kovi&#263;</surname><given-names>F</given-names></name><etal/></person-group><article-title>Anastrozole and tamoxifen impact on IgG glycome composition dynamics in luminal A and luminal B breast cancers</article-title><source>Antibodies</source><year>2024</year><volume>13</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.3390/antib13010009</pub-id><pub-id pub-id-type="pmid">38390870</pub-id><pub-id pub-id-type="pmcid">PMC10885039</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Rap&#269;an B, Fan&#269;ovi&#263; M, Pribi&#263; T, Kirac I, Ga&#263;e M, Vu&#269;kovi&#263; F, et al. Anastrozole and tamoxifen impact on IgG glycome composition dynamics in luminal A and luminal B breast cancers. Antibodies. 2024;13:9. 10.3390/antib13010009.<pub-id pub-id-type="pmid">38390870</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antib13010009</pub-id><pub-id pub-id-type="pmcid">PMC10885039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>R</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Qin</surname><given-names>W</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name></person-group><article-title>Prediction of neoadjuvant chemotherapeutic efficacy in patients with locally advanced gastric cancer by serum IgG glycomics profiling</article-title><source>Clin Proteom</source><year>2020</year><volume>17</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/s12014-020-9267-8</pub-id><pub-id pub-id-type="pmcid">PMC7003487</pub-id><pub-id pub-id-type="pmid">32042279</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Qin R, Yang Y, Chen H, Qin W, Han J, Gu Y, Pan Y, Cheng X, Zhao J, Wang X, Ren S, Sun Y, Gu J. Prediction of neoadjuvant chemotherapeutic efficacy in patients with locally advanced gastric cancer by serum IgG glycomics profiling. Clin Proteom. 2020;17:4. 10.1186/s12014-020-9267-8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12014-020-9267-8</pub-id><pub-id pub-id-type="pmcid">PMC7003487</pub-id><pub-id pub-id-type="pmid">32042279</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#352;tambuk</surname><given-names>J</given-names></name><name name-style="western"><surname>Vu&#269;kovi&#263;</surname><given-names>F</given-names></name><name name-style="western"><surname>Habazin</surname><given-names>S</given-names></name><name name-style="western"><surname>Hani&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Novokmet</surname><given-names>M</given-names></name><name name-style="western"><surname>Nikolaus</surname><given-names>S</given-names></name><etal/></person-group><article-title>Distinct longitudinal changes in Immunoglobulin G N-glycosylation associate with therapy response in chronic inflammatory diseases</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><fpage>8473</fpage><pub-id pub-id-type="doi">10.3390/ijms23158473</pub-id><pub-id pub-id-type="pmid">35955616</pub-id><pub-id pub-id-type="pmcid">PMC9368836</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">&#352;tambuk J, Vu&#269;kovi&#263; F, Habazin S, Hani&#263; M, Novokmet M, Nikolaus S, et al. Distinct longitudinal changes in Immunoglobulin G N-glycosylation associate with therapy response in chronic inflammatory diseases. Int J Mol Sci. 2022;23:8473. 10.3390/ijms23158473.<pub-id pub-id-type="pmid">35955616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23158473</pub-id><pub-id pub-id-type="pmcid">PMC9368836</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pu&#269;i&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Kne&#382;evi&#263;</surname><given-names>A</given-names></name><name name-style="western"><surname>Vidi&#269;</surname><given-names>J</given-names></name><name name-style="western"><surname>Adamczyk</surname><given-names>B</given-names></name><name name-style="western"><surname>Novokmet</surname><given-names>M</given-names></name><name name-style="western"><surname>Pola&#353;ek</surname><given-names>O</given-names></name><etal/></person-group><article-title>High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations</article-title><source>Mol Cell Proteom</source><year>2011</year><volume>10</volume><fpage>M111010090</fpage><pub-id pub-id-type="doi">10.1074/mcp.M111.010090</pub-id><pub-id pub-id-type="pmcid">PMC3205872</pub-id><pub-id pub-id-type="pmid">21653738</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Pu&#269;i&#263; M, Kne&#382;evi&#263; A, Vidi&#269; J, Adamczyk B, Novokmet M, Pola&#353;ek O, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteom. 2011;10:M111010090. 10.1074/mcp.M111.010090.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/mcp.M111.010090</pub-id><pub-id pub-id-type="pmcid">PMC3205872</pub-id><pub-id pub-id-type="pmid">21653738</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peipp</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Bueren</surname><given-names>JJL</given-names></name><name name-style="western"><surname>Schneider-Merck</surname><given-names>T</given-names></name><name name-style="western"><surname>Bleeker</surname><given-names>WWK</given-names></name><name name-style="western"><surname>Dechant</surname><given-names>M</given-names></name><name name-style="western"><surname>Beyer</surname><given-names>T</given-names></name><etal/></person-group><article-title>Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>2390</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-03-144600</pub-id><pub-id pub-id-type="pmid">18566325</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Peipp M, Van Bueren JJL, Schneider-Merck T, Bleeker WWK, Dechant M, Beyer T, et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood. 2008;112:2390&#8211;9. 10.1182/blood-2008-03-144600.<pub-id pub-id-type="pmid">18566325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2008-03-144600</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junttila</surname><given-names>TT</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>K</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>GL</given-names></name><name name-style="western"><surname>Sliwkowski</surname><given-names>MX</given-names></name></person-group><article-title>Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2011</year><volume>128</volume><fpage>347</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1007/s10549-010-1090-x</pub-id><pub-id pub-id-type="pmid">20730488</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128:347&#8211;56. 10.1007/s10549-010-1090-x.<pub-id pub-id-type="pmid">20730488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-010-1090-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Modica</surname><given-names>M</given-names></name><name name-style="western"><surname>Sfondrini</surname><given-names>L</given-names></name><name name-style="western"><surname>Regondi</surname><given-names>V</given-names></name><name name-style="western"><surname>Varchetta</surname><given-names>S</given-names></name><name name-style="western"><surname>Oliviero</surname><given-names>B</given-names></name><name name-style="western"><surname>Mariani</surname><given-names>G</given-names></name><etal/></person-group><article-title>Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>255</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6353</pub-id><pub-id pub-id-type="pmid">26595802</pub-id><pub-id pub-id-type="pmcid">PMC4807996</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Di Modica M, Sfondrini L, Regondi V, Varchetta S, Oliviero B, Mariani G, et al. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget. 2016;7:255&#8211;65. 10.18632/oncotarget.6353.<pub-id pub-id-type="pmid">26595802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.6353</pub-id><pub-id pub-id-type="pmcid">PMC4807996</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Ugonotti</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>LY</given-names></name><name name-style="western"><surname>Everest-Dass</surname><given-names>A</given-names></name><name name-style="western"><surname>Kawahara</surname><given-names>R</given-names></name><name name-style="western"><surname>Thaysen-Andersen</surname><given-names>M</given-names></name></person-group><article-title>Trends in oligomannosylation and &#945;1,2-mannosidase expression in human cancers</article-title><source>Oncotarget</source><year>2021</year><volume>12</volume><fpage>2188</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.28064</pub-id><pub-id pub-id-type="pmid">34676051</pub-id><pub-id pub-id-type="pmcid">PMC8522845</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Chatterjee S, Ugonotti J, Lee LY, Everest-Dass A, Kawahara R, Thaysen-Andersen M. Trends in oligomannosylation and &#945;1,2-mannosidase expression in human cancers. Oncotarget. 2021;12:2188&#8211;205. 10.18632/oncotarget.28064.<pub-id pub-id-type="pmid">34676051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.28064</pub-id><pub-id pub-id-type="pmcid">PMC8522845</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#352;&#269;up&#225;kov&#225;</surname><given-names>K</given-names></name><name name-style="western"><surname>Adelaja</surname><given-names>OT</given-names></name><name name-style="western"><surname>Balluff</surname><given-names>B</given-names></name><name name-style="western"><surname>Ayyappan</surname><given-names>V</given-names></name><name name-style="western"><surname>Tressler</surname><given-names>CM</given-names></name><name name-style="western"><surname>Jenkinson</surname><given-names>NM</given-names></name><etal/></person-group><article-title>Clinical importance of high-mannose, fucosylated, and complex N-glycans in breast cancer metastasis</article-title><source>JCI Insight</source><year>2021</year><pub-id pub-id-type="doi">10.1172/jci.insight.146945</pub-id><pub-id pub-id-type="pmid">34752419</pub-id><pub-id pub-id-type="pmcid">PMC8783675</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">&#352;&#269;up&#225;kov&#225; K, Adelaja OT, Balluff B, Ayyappan V, Tressler CM, Jenkinson NM, et al. Clinical importance of high-mannose, fucosylated, and complex N-glycans in breast cancer metastasis. JCI Insight. 2021. 10.1172/jci.insight.146945.<pub-id pub-id-type="pmid">34752419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.146945</pub-id><pub-id pub-id-type="pmcid">PMC8783675</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>JW</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>K-H</given-names></name><name name-style="western"><surname>You</surname><given-names>JW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JW</given-names></name><name name-style="western"><surname>Moon</surname><given-names>B-I</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Serum levels and glycosylation changes of Alpha-1-Acid glycoprotein according to severity of breast cancer in Korean women</article-title><source>J Microbiol Biotechnol</source><year>2020</year><volume>30</volume><fpage>1297</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.4014/jmb.2006.06007</pub-id><pub-id pub-id-type="pmid">32627751</pub-id><pub-id pub-id-type="pmcid">PMC9728234</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Choi JW, Jeong K-H, You JW, Lee JW, Moon B-I, Kim HJ, et al. Serum levels and glycosylation changes of Alpha-1-Acid glycoprotein according to severity of breast cancer in Korean women. J Microbiol Biotechnol. 2020;30:1297&#8211;304. 10.4014/jmb.2006.06007.<pub-id pub-id-type="pmid">32627751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4014/jmb.2006.06007</pub-id><pub-id pub-id-type="pmcid">PMC9728234</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chantziou</surname><given-names>A</given-names></name><name name-style="western"><surname>Theodorakis</surname><given-names>K</given-names></name><name name-style="western"><surname>Polioudaki</surname><given-names>H</given-names></name><name name-style="western"><surname>de Bree</surname><given-names>E</given-names></name><name name-style="western"><surname>Kampa</surname><given-names>M</given-names></name><name name-style="western"><surname>Mavroudis</surname><given-names>D</given-names></name><etal/></person-group><article-title>Glycosylation modulates plasma membrane trafficking of CD24 in breast cancer cells</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><fpage>8165</fpage><pub-id pub-id-type="doi">10.3390/ijms22158165</pub-id><pub-id pub-id-type="pmid">34360932</pub-id><pub-id pub-id-type="pmcid">PMC8347636</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Chantziou A, Theodorakis K, Polioudaki H, de Bree E, Kampa M, Mavroudis D, et al. Glycosylation modulates plasma membrane trafficking of CD24 in breast cancer cells. Int J Mol Sci. 2021;22:8165. 10.3390/ijms22158165.<pub-id pub-id-type="pmid">34360932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22158165</pub-id><pub-id pub-id-type="pmcid">PMC8347636</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Guan</surname><given-names>F</given-names></name><etal/></person-group><article-title>Bisecting N-acetylglucosamine on EGFR inhibits malignant phenotype of breast cancer via down-regulation of EGFR/Erk signaling</article-title><source>Front Oncol</source><year>2020</year><pub-id pub-id-type="doi">10.3389/fonc.2020.00929</pub-id><pub-id pub-id-type="pmid">32612952</pub-id><pub-id pub-id-type="pmcid">PMC7308504</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Cheng L, Cao L, Wu Y, Xie W, Li J, Guan F, et al. Bisecting N-acetylglucosamine on EGFR inhibits malignant phenotype of breast cancer via down-regulation of EGFR/Erk signaling. Front Oncol. 2020. 10.3389/fonc.2020.00929.<pub-id pub-id-type="pmid">32612952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2020.00929</pub-id><pub-id pub-id-type="pmcid">PMC7308504</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>